What is Ramipril For?
Ramipril is an ACE inhibitor used primarily for treating hypertension, reducing cardiovascular events in high-risk patients, managing heart failure after myocardial infarction, and slowing progression of diabetic kidney disease.
FDA-Approved Indications
Based on the drug label, ramipril has three core FDA-approved uses 1:
1. Hypertension
- Used alone or combined with thiazide diuretics
- Typical dosing: 2.5-20 mg once or twice daily 2, 3
- Reduces both systolic and diastolic blood pressure with effects lasting 24 hours 1
2. Heart Failure Post-Myocardial Infarction
- For stable patients showing signs of congestive heart failure within days after acute MI
- Decreases risk of death (principally cardiovascular death), heart failure-related hospitalization, and progression to severe/resistant heart failure 1
- In the AIRE trial, ramipril reduced all-cause mortality by 27% (p=0.002) in post-MI patients with heart failure 1
- Typical dosing: Start 2.5 mg twice daily, titrate to target of 5 mg twice daily 1
3. Cardiovascular Risk Reduction in High-Risk Patients
- The landmark HOPE trial demonstrated that ramipril 10 mg daily reduced the composite outcome of cardiovascular death, MI, and stroke by 22% in high-risk patients (≥55 years with vascular disease or diabetes plus other risk factors) without heart failure or low ejection fraction 4, 5
- Individual outcomes: MI reduced by 22%, stroke by 33%, cardiovascular death by 37% 4
- Benefits were independent of blood pressure reduction 5
Guideline-Supported Uses
Coronary Artery Disease
- Class I recommendation: ACE inhibitors (including ramipril) should be used in all patients with CAD who also have diabetes and/or left ventricular systolic dysfunction 4
- Class IIa: Reasonable for patients with CAD or other vascular disease even without diabetes or LV dysfunction 4
Diabetes with Cardiovascular Risk
- In the MICRO-HOPE substudy, ramipril reduced MI by 22%, stroke by 33%, cardiovascular death by 37%, and overt nephropathy by 24% in diabetic patients 4
- Reduced development of new diabetes in non-diabetic patients 4
Chronic Kidney Disease with Diabetes
- ACE inhibitors are preferred agents for diabetic kidney disease with microalbuminuria or macroalbuminuria 6
- Target blood pressure <130/80 mmHg 6
- Starting dose: 1.25 mg daily if creatinine clearance <40 mL/min, titrate to 1.25-20 mg daily 6
Heart Failure with Reduced Ejection Fraction (HFrEF)
- Class I recommendation: ACE inhibitors reduce mortality by 17% and are foundational therapy for all HFrEF patients unless contraindicated 7, 8
- Ramipril dosing for HFrEF: Start 1.25-2.5 mg once daily, target 10 mg once daily 7, 8
- Should be combined with beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors as part of guideline-directed medical therapy 8
Key Dosing Considerations
Renal impairment: Dose adjustment required if creatinine clearance <30 mL/min (initial dose 1.25 mg daily, maximum 5 mg/day) 9
Contraindications:
- History of angioedema with ACE inhibitors
- Pregnancy
- Bilateral renal artery stenosis
- Do NOT combine with ARBs or direct renin inhibitors - the ONTARGET trial showed combination therapy with ramipril plus telmisartan increased adverse events (syncope, renal impairment) without additional cardiovascular benefit 10